BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cobra Biologics Ltd. and Alligator Bioscience Sign Monoclonal Antibody Manufacturing Agreement


6/12/2012 6:28:33 AM

June 12, 2012 -- Cobra Biologics, the international clinical and commercial manufacturer of biologics and pharmaceuticals and Alligator Bioscience AB today announce that they have entered into a manufacturing services and supply agreement for the production of monoclonal antibody Drug Substance and Drug Product for pre-clinical studies and Phase I-II clinical trials.

Under the terms of the agreement, Cobra will be providing cell line development through its maxXpress service, GMP cell banking, analytical and process development, scale-up, toxicology and GMP supplies, as well as stability studies and QP release for clinical trials.

Peter Coleman, CEO of Cobra Biologics said: "Having been through a rigorous selection process, we are very pleased to have been chosen by Alligator. We believe that our comprehensive service offering, right from our excellent cell line development capability through to fill/finish at our recently acquired Matfors facility (Sweden) enabled us to win this important program with Alligator in a highly competitive market place. We look forward to building a lasting relationship with Alligator Bioscience.”

Alligator will be taking advantage of Cobra’s maxXpress service, which combines the UCOE protein expression technology with the experience and expertise of Cobra Biologics’ cell line development team and the Cello™ robotic clone selection system, to enable rapid clone selection and production of the monoclonal antibody.

For more information about Cobra Biologics, please contact Peter Coleman, CEO, on +44 (0)1782 714181 or email peter.coleman@cobrabio.com

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0)207 861 3019 or email: t.jervis@defacto.com.

About Cobra Biologics

Cobra Biologics is a leading international clinical and commercial manufacturer of biologics and pharmaceuticals with three GMP approved facilities. We offer a broad range of integrated and stand-alone development services, stretching from cell line development through to the commercial supply of investigational medicinal product. We take pride in manufacturing excellence and being a trusted provider, delivering what we promise and helping our customers to develop drugs for the benefit of patients. Cobra Biologics provides manufacturing solutions to the biologics and pharmaceutical industry covering antibodies, recombinant proteins, viruses, DNA, cellular therapeutics and small molecules.

www.cobrabio.com

About Alligator Bioscience AB

Alligator Bioscience discovers and develops innovative biotherapeutics for cancer. Drug discovery and development at Alligator Bioscience spans early research phases with lead identification up to proof of concept phase I/II studies in patients. Alligator Bioscience has three proprietary projects in its pipeline.

To support the discovery of drug candidates Alligator Bioscience is using its two pipeline enabling technologies: a fully human scFv antibody library (SCALA-11) and a proprietary protein optimization technology FIND® (Fragment INduced Diversity).

Alligator Bioscience is a privately held company based in Lund, Sweden.

www.alligatorbioscience.com

Tristan Jervis | Director

Holborn Gate, 26 Southampton Buildings

London WC2A 1BP

Telephone: +44 (0)207 861 3838

Direct: +44 (0)207 861 3019

Fax: +44 (0)207 861 3839

E-mail: t.jervis@defacto.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES